A bench to bedside approach is used in our studies of human genetic disorders, integrating both basic and clinical research. We focus both on a rare genetic disorder, Gaucher disease, and a common complex disorder, Parkinson disease. Most inherited diseases are characterized by a wide range of patient presentations, yet the factors contributing to this heterogeneity are elusive. Gaucher disease, the most common of the sphingolipidoses, is studied as a prototype because of the broad spectrum of clinical diversity resulting from this recessively inherited enzyme deficiency. Gaucher disease affects approximately 10,000 to 20,000 Americans and is more common among Ashkenazi Jews. Natural history studies, as well as molecular and biochemical evaluations in humans and animals, are used to enhance our understanding of heterogeneity in Gaucher disease and our ability to develop rational therapy for patients. The techniques, insights, and experience gained can then be applied to other Mendelian disorders and ultimately to the challenges of complex illnesses Our clinical and molecular studies have shown that there is significant genotypic heterogeneity among clinically similar patients. Moreover, the vastly different phenotypes encountered among patients with Gaucher disease are not adequately predicted by genotype. These observations are true with many different genetic disorders. Thus we are exploring other genetic or environmental factors contributing to the phenotypes seen and are studying factors involved in the regulation of glucocerebrosidase. Recombination events within and around the glucocerebrosidase locus, and newly discovered contiguous genes, may potentially have a critical role. Transgenic and knock-out mice are used to facilitate our understanding of the pathogenesis and treatment of lysosomal storage disorders and the phenotypic consequences of specific genotypes. Murine models led to the recognition of a new lethal human Gaucher phenotype, the involvement of the substrate glycosylsphingosine, the role of glucocerebrosidase in skin morphology and function, and the identification of a novel contiguous gene, metaxin. Comparative genomics and protein modeling studies utilizing the three dimensional structure of the enzyme are also helping us to better understand the consequences and regulation of the mutant protein. We also focus on patients with Gaucher disease who display atypical manifestations including parkinsonism, myoclonic epilepsy, cardiac and renal involvement and collodion skin. Understanding the mechanisms leading to these diverse phenotypes may help in the identification of modifier genes, and will provide insights relevant to other disorders. An important consequence of in our research has been the discovery of an association between Gaucher disease and parkinsonism. Our clinical studies of patients with disorders, neuropathologic evaluations, family studies and screening of tissues and DNA samples from subjects with Parkinson disease have all supported this link. Evaluations of patients with Gaucher disease and Parkinson disease demonstrate both classic and atypical features. Many different genotypes are encountered. Currently, prospective studies of these subjects and their affected or at-risk relatives using Positron Emission Tomography studies of the brain as well as other diagnostic modalities are in progress. Neuropathology from several of these cases demonstrated large, immunoreactive Lewy bodies in the substantia nigra and changes in brain hippocampal layers CA2-CA4, a region of vulnerability also in diffuse Lewy body disease. Glucocerebrosidase appears to be located in these inclusions. Furthermore, family histories of families of patients with Gaucher disease identified several carrier relatives who developed parkinsonism. This prompted an examination of the glucocerebrosidase gene (GBA) in large cohorts with Parkinson disease. Complete gene sequencing of GBA was initially performed in brain samples from individuals who died carrying the clinical and/or pathologic diagnosis of Parkinson disease and demonstrated that a significant number had mutations in GBA. Glucocerebrosidase mutations were also identified in samples from patients with the diagnosis diffuse Lewy body dementia. These studies indicate that an alteration in glucocerebrosidase, even in heterozygotes, contribute to a vulnerability to synecleinopathies. This finding has been replicated in other large Parkinson cohorts, suggesting that mutations in glucocerebrosidase are a frequent inherited risk factor associated with parkinsonism. We have coordinated a large multi-center collaborative study including subjects seen at 16 centers around the world. This study of over 5000 patients with Parkinson disease and an equal number of controls demonstrates that the odds ratio for carrying a GBA mutation is greater than 5, rendering glucocerebrosidase among the most common risk factors for parkinsonism known to date. This project demonstrates how studies of a rare metabolic disorder, Gaucher disease, may provide a window into both the genetics and pathogenesis of a common complex disorder, Parkinson disease. Another important goal is to develop new treatment strategies for patients. Enzyme replacement therapy for Gaucher disease with imiglucerase has been shown to be clinically effective, but its extremely high cost is of considerable concern both to the public and to health care providers. A potential alternative therapy is the use of small molecules that may function as chemical chaperones that can stabilize and enhance the patient s mutant enzyme. This approach is being explored by studies of the trafficking of glucocerebrosidase and investigations of whether small molecules may enhance the delivery of mutant glucocerebrosidase to the lysosome. In collaboration with Dr. Chris Austin (NHGRI), we have screened large libraries of compounds and have identified several three different structural classes of chemical chaperones that may serve as the basis for new therapies. Further high throughput strategies are being developed using mutant forms of the enzymes as well as other lysosomal enzymes.
| Davidson, Brad A; Hassan, Shahzeb; Garcia, Eric Joshua et al. (2018) Exploring genetic modifiers of Gaucher disease: The next horizon. Hum Mutat 39:1739-1751 |
| Gary, Sam E; Ryan, Emory; Steward, Alta M et al. (2018) Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab 13:107-118 |
| Danilov, Sergei M; Tikhomirova, Victoria E; Metzger, Roman et al. (2018) ACE phenotyping in Gaucher disease. Mol Genet Metab 123:501-510 |
| Hassan, Shahzeb; Lopez, Grisel; Stubblefield, Barbara K et al. (2018) Alleles with more than one mutation can complicate genotype/phenotype studies in Mendelian disorders: Lessons from Gaucher disease. Mol Genet Metab 125:1-3 |
| Roshan Lal, Tamanna; Sidransky, Ellen (2017) The Spectrum of Neurological Manifestations Associated with Gaucher Disease. Diseases 5: |
| Borger, Daniel K; McMahon, Benjamin; Roshan Lal, Tamanna et al. (2017) Induced pluripotent stem cell models of lysosomal storage disorders. Dis Model Mech 10:691-704 |
| Aflaki, Elma; Borger, Daniel K; Grey, Richard J et al. (2017) Efferocytosis is impaired in Gaucher macrophages. Haematologica 102:656-665 |
| Hassan, Shahzeb; Sidransky, Ellen; Tayebi, Nahid (2017) The role of epigenetics in lysosomal storage disorders: Uncharted territory. Mol Genet Metab 122:10-18 |
| Tayebi, Nahid; Parisiadou, Loukia; Berhe, Bahafta et al. (2017) Glucocerebrosidase haploinsufficiency in A53T ?-synuclein mice impacts disease onset and course. Mol Genet Metab 122:198-208 |
| Mistry, Pramod K; Lopez, Grisel; Schiffmann, Raphael et al. (2017) Gaucher disease: Progress and ongoing challenges. Mol Genet Metab 120:8-21 |
Showing the most recent 10 out of 94 publications
